Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity
Abstract
Adenovirus serotype 5 (Ad5) is a commonly used viral vector for transient delivery of transgenes, primarily for vaccination against pathogen and tumor antigens. However, endemic infections with Ad5 produce virus-specific neutralizing antibodies (NAbs) that limit transgene delivery and constrain target-directed immunity following exposure to Ad5-based vaccines. Indeed, clinical trials have revealed the limitations that virus-specific NAbs impose on the efficacy of Ad5-based vaccines. In that context, the emerging focus on immunological approaches targeting cancer self-antigens or neoepitopes underscores the unmet therapeutic need for more efficacious vaccine vectors.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 01, 2020
- Source ID
- 10.1136/jitc-2020-001046
Entities
People
- Adam E. Snook
- Amanda Pattison
- Babar Bashir
- Elinor Leong
- Ellen Caparosa
- Jagmohan Singh
- Jamin Roh
- Jeffrey A. Rappaport
- John C. Flickinger Jr.
- Joshua R. Barton
- Robert D Carlson
- Scott A. Waldman
- Tingting Zhan
- Trevor R Baybutt
Organizations
- DeGregorio Family Foundation
- National Institutes of Health
- Pennsylvania Department of Health
- Pharmaceutical Research and Manufacturers of America
- United States Department of Defense